GMED / Globus Medical, Inc. (GMED) CEO Dan Scavilla on Q1 2022 Results - Earnings Call Transcript

Globus Medical, Inc. shares have seen a significant pullback after announcing a $3 billion deal to acquire NuVasive. The company has a strong track re more_horizontal

Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is de more_horizontal

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most more_horizontal

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies. more_horizontal

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to more_horizontal

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system. more_horizontal

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Globus Medical (GMED). But which of t more_horizontal

Globus Medical's Q1 sales grew by 21% YoY to a record $277m, driven by robust musculoskeletal sales and demand for its robotics offerings. The company more_horizontal